Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer

An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 17 August →